A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol

BACKGROUND: Radioactive iodine (RAI) remnant ablation is recommended in patients with papillary thyroid cancer (PTC) and extrathyroidal extension or central lymph node metastasis. However, there exists little evidence about the necessity of remnant ablation in PTC patients with low- to intermediate-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eun Kyung, Lee, You Jin, Park, Young Joo, Moon, Jae Hoon, Yi, Ka Hee, Kim, Koon Soon, Lee, Joo Hee, Cho, Sun Wook, Joo, Jungnam, Hwangbo, Yul, Go, Sujeong, Park, Do Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520583/
https://www.ncbi.nlm.nih.gov/pubmed/32981299
http://dx.doi.org/10.3803/EnM.2020.681

Ejemplares similares

Ejemplares similares